Janakiraman Subramanian, MD

Articles

Dr. Subramanian on the Potential Utility of Dostarlimab in Previously Treated NSCLC

November 17th 2020

Janakiraman Subramanian, MD, discusses the potential utility of dostarlimab in ​previously treated patients with non–small cell lung cancer.

Dr. Subramanian on the IMpower131 Trial in Squamous NSCLC

March 27th 2019

Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses the IMpower131 trial in advanced squamous non–small cell lung cancer (NSCLC).

Dr. Subramanian Discusses Tumor Biology in Lung Cancer

February 23rd 2019

Janakiraman Subramanian, MD, a medical oncologist and director of thoracic oncology and director of the Center for Precision Medicine at Saint Luke’s Cancer Institute, discusses tumor biology in lung cancer.

Dr. Subramanian on the Future of Immunotherapy in NSCLC

February 9th 2019

Janakiraman Subramanian, MD, a medical oncologist and director of thoracic oncology and director of the Center for Precision Medicine at St. Luke’s Cancer Institute, discusses the future of immunotherapy in non–small cell lung cancer (NSCLC).

Dr. Subramanian on Ongoing Trials for Patients With Nonsquamous NSCLC

January 16th 2019

Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses ongoing trials evaluating the use of immunotherapy in patients with nonsquamous non–small cell lung cancer (NSCLC).

x